Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Bristol-Myers Squibb-Sponsored Partnering for Cure(TM) Programme Announces New Winning Projects Designed to Investigate Novel Ways to Cure Viral Diseases


News provided by

Bristol-Myers Squibb

11 Nov, 2014, 12:48 GMT

Share this article

Share toX

Share this article

Share toX

PARIS, November 11, 2014 /PRNewswire/ --

The Partnering for Cure faculty of experts today announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV). As part of Bristol-Myers Squibb's ongoing commitment in virology, these awards provide an opportunity for European researchers, particularly junior faculty and young investigators, to accelerate novel solutions that could lead to cures in chronic viral infections.

To view the Multimedia News Release, please click:

http://www.multivu.com/players/English/72762592-bristol-myers-squibb-cure-programme/  

The recipients of the 2014 Partnering for Cure research awards include:

  • Elisa De Crignis (the Netherlands) - Human liver organoids: a novel technology to unravel Determinants of HBV infection and persistence
  • Salim Khakoo (UK) - Predictive factors to define candidates for stopping antiviral therapy with Nucleos(t)ides analogues in chronic HBeAg-negative hepatitis B
  • Pedro Borrego (Portugal) - Gene therapy for HIV cure using RNA replicons targeting HIV entry and latency
  • Godelieve de Bree (the Netherlands) - The properties of the lymphoid viral reservoir and the HIV specific CD8+ T cell response in early treatment of acute HIV infection

Bristol-Myers Squibb will allocate over €300,000 to support the four research projects.

The announcement follows a year of intense activity for the programme, reflecting the rapidly evolving arena of HIV and hepatitis cure research. Events bringing together leading physicians and researchers across Europe have focused on topics ranging from the treatment challenges in the management of patients with HIV infection to unresolved cure challenges in HBV and HCV.

Professor Jürgen Rockstroh, Chair of the Partnering for Cure Faculty, commented, "We are delighted to announce this year's research winners. Since the programme was founded last year, Partnering for Cure has enabled novel research into viral diseases to progress, while also facilitating the exchange of knowledge among industry-leading virology experts. These activities are vital in helping to discover future cures for diseases such as hepatitis and HIV."

The announcement follows two major scientific conferences held this year that emphasised the still largely unmet medical needs of patients with viral diseases. The 20th International AIDS Conference, held in July, explored progress towards HIV cure and the current scientific and social challenges still faced by researchers, as well as healthcare providers. More recently, this month the American Association for the Study of Liver Diseases (AASLD) hosted the annual Liver Meeting which examined recent progress in HCV cure and the treatment options that are now available to patients.

George Hanna MD, Vice President, Virology Development at Bristol-Myers Squibb, remarked, "Bristol-Myers Squibb has a long-standing commitment to the fight against viral diseases. Through the Partnering for Cure programme and this latest round of awards, we are pledging our continued commitment to virology education, treatment and research." 

About Partnering for Cure 

Partnering for Cure is a European medical education programme developed as part of Bristol-Myers Squibb's ongoing commitment to virology research, education and transforming clinical outcomes for patients with chronic viral diseases. The programme focuses on recent and ongoing cure research in HIV, HBV and HCV.

The objectives of the programme are to:

  • Provide medical education to physicians interested in virology cure research
  • Provide support to researchers active in virology cure research
  • Provide a forum for physicians and researchers to discuss advances in virology cure

The Partnering for Cure initiative reinforces Bristol-Myers Squibb's commitment in virology, which is rooted in the company's legacy in virology and ongoing research in HIV and viral hepatitis. Chronic viral infections make a substantial contribution to the burden of chronic diseases and premature mortality worldwide. The World Health Organisation (WHO) estimated that in 2013, more than 1.5 million people died as a result of HIV-related causes.[1] WHO also attributes over one million deaths to viral hepatitis infection each year.[2] Infections with hepatitis B and C viruses also cause an estimated 57 percent of cases of liver cirrhosis and 78 percent of cases of primary liver cancer annually.[3] Whilst important advances have been made over the last decade, significant unmet needs and the opportunity for cure remains, particularly in HIV.

Bristol-Myers Squibb's Commitment to Virology 

For over 20 years, Bristol-Myers Squibb has worked collaboratively with the virology community to help meet the needs of patients living with HIV, HBV and HCV - by providing and developing medicines such as Zerit®, Videx®, Sustiva®, Atripla®*, Reyataz®, Baraclude®, Daklinza®, supporting clinical research on new innovative compounds, supporting disease education efforts, and improving access to medicines in the developing world.

Bristol-Myers Squibb supports a number of scientific and educational programs within the virology community around the world that encompass disease education, disease awareness and sharing of best practices. In addition to Partnering for Cure these include SHE® (Strong, HIV positive, Empowered Women/Strong, HIV positive Women Educational Programme), a comprehensive and innovative programme for women living with HIV and their healthcare providers, PATH B® (Patients and professionals acting together for hepatitis B), a joint initiative between hepatitis patient groups and hepatologists to provide comprehensive information and support for patients with chronic hepatitis B.

Additionally, Bristol-Myers Squibb Foundation's philanthropic and educational programmes, such as Secure the Future® and Delivering Hope®, aim to support people living with HIV in Africa and with viral hepatitis in Asia, through numerous private-public partnerships and community based projects.

* Atripla® is a trademark of Bristol-Myers Squibb Co. and Gilead Sciences, Inc. 

1. World Health Organization. HIV/AIDS statistics. 2014. Available at: http://www.who.int/mediacentre/factsheets/fs360/en/ . Last accessed: September 2014 

2. World Health Organization. Global Alert and Response (GAR): Hepatitis. 2014. Available at: http://www.who.int/csr/disease/hepatitis/world_hepatitis_day/question_answer/en/. Last accessed: September 2014. 

3. WHO and WHA, Global Policy Report on the Prevention and Control of Viral Hepatitis, 2013, http://global-report.worldhepatitisalliance.org/en/home.html  

Video: 
     http://www.multivu.com/players/English/72762592-bristol-myers-squibb-cure-programme/

Mercury ID: VIRUK14NP09803-01
Date of preparation: November 2014

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.